Skip to main content
News & Events December 2, 2021

Perkins’ Head of Molecular Endocrinology and Pharmacology, Professor Kevin Pfleger, was appointed President of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) earlier this month. Coincidentally, on the same day, Prof Pfleger was announced as a Fellow of the British Pharmacological Society.

ASCEPT is the peak professional society devoted to advancing excellence in Clinical and Experimental Pharmacology and Toxicology in Australia and New Zealand. Established in 1966, ASCEPT is affiliated with the International Union of Basic and Clinical Pharmacology (IUPHAR) and the International Union of Toxicology (IUTOX). Prof Pfleger has served on the ASCEPT Board since 2016 and was Chair of the Scientific Advisory Committee in 2017 and 2018.

“I am honoured to be appointed President of ASCEPT, and am particularly excited given the Society’s conference will be held in Perth next year, in collaboration with the Australasian Pharmaceutical Science Association (APSA).”

As well, ASCEPT is pleased to announce a new Special Interest Group for Innovation and Industry, co-Chaired by Professor Pfleger and Professor Emeritus Daniel Hoyer of the University of Melbourne. Please reach out to Kevin or Daniel for more information and to get involved, particularly if you have industry experience.

The British Pharmacological Society, established in 1931, has a mission to promote and advance the whole spectrum of pharmacology. It has members from more than 60 countries worldwide, and Professor Pfleger serves on its International Advisory Group.

Fellows have demonstrated distinction and peer recognition in pharmacology, through their work, publication and presentation of research, leadership, and contribution to Society life.

Through their work, Fellows further all disciplines of pharmacology in the discovery, development and use of medicines. Through their leadership, and contribution to Society life, they inspire and support members at earlier stages of their career or study.


Related news: British Pharmacological Society LinkedIn post